These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 37024824)

  • 1. Efficacy and safety of transurethral resection of bladder tumour combined with chemotherapy and immunotherapy in bladder-sparing therapy in patients with T1 high-grade or T2 bladder cancer: a protocol for a randomized controlled trial.
    Yang X; Zhang S; Cui Y; Li Y; Song X; Pang J
    BMC Cancer; 2023 Apr; 23(1):320. PubMed ID: 37024824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of noninvasive down-staging after transurethral resection of bladder tumor plus systemic chemotherapy on bladder-sparing strategy in patients with muscle-invasive bladder cancer.
    Onishi T; Sekito S; Shibahara T; Yabana T
    Urol Oncol; 2021 Feb; 39(2):132.e1-132.e6. PubMed ID: 32792215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence and outcomes of transurethral resection versus radical cystectomy for muscle-infiltrating bladder cancer in the United States: A population-based cohort study.
    Zheng Y; Ye Y; Chen J; Wei Z; Liu Z; Yu K; Zhang X
    Int J Surg; 2022 Jul; 103():106693. PubMed ID: 35690361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intra-arterial chemotherapy for muscle-invasive bladder cancer following transurethral resection.
    Liang S; Zou Q; Han B; Jing Y; Cui D; An X; Gao Y; Hu J; Xia S
    Urol Int; 2015; 94(4):406-11. PubMed ID: 25678415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of high-risk non-muscle invasive bladder cancer.
    Brausi M; Olaru V
    Minerva Urol Nefrol; 2012 Dec; 64(4):255-60. PubMed ID: 23288212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluorescent cystoscopy-assisted en bloc transurethral resection versus conventional transurethral resection in patients with non-muscle invasive bladder cancer: study protocol of a prospective, open-label, randomized control trial (the FLEBER study).
    Miyake M; Nishimura N; Inoue T; Suzuki S; Fujii T; Owari T; Hori S; Nakai Y; Toritsuka M; Nakagawa H; Tsukamoto S; Anai S; Torimoto K; Yoneda T; Tanaka N; Fujimoto K
    Trials; 2021 Feb; 22(1):136. PubMed ID: 33579327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival and oncologic outcomes of complete transurethral resection of bladder tumor prior to neoadjuvant chemotherapy for muscle-invasive bladder cancer.
    Pak JS; Haas CR; Anderson CB; DeCastro GJ; Benson MC; McKiernan JM
    Urol Oncol; 2021 Nov; 39(11):787.e9-787.e15. PubMed ID: 33865688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical significance of a second transurethral resection for T1 high-grade bladder cancer: Results of a prospective study.
    Shim JS; Choi H; Noh TI; Tae JH; Yoon SG; Kang SH; Bae JH; Park HS; Park JY
    Korean J Urol; 2015 Jun; 56(6):429-34. PubMed ID: 26078839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.
    Di Stasi SM; Valenti M; Verri C; Liberati E; Giurioli A; Leprini G; Masedu F; Ricci AR; Micali F; Vespasiani G
    Lancet Oncol; 2011 Sep; 12(9):871-9. PubMed ID: 21831711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy.
    Hagan MP; Winter KA; Kaufman DS; Wajsman Z; Zietman AL; Heney NM; Toonkel LM; Jones CU; Roberts JD; Shipley WU
    Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):665-72. PubMed ID: 14529770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant Chemotherapy-Guided Bladder-Sparing Treatment for Muscle-Invasive Bladder Cancer: Results of a Pilot Phase II Study.
    Shi H; Zhang W; Bi X; Wang D; Xiao Z; Guan Y; Guan K; Tian J; Bai H; Hu L; Cao C; Jiang W; Hu Z; Zhang J; Chen Y; Zheng S; Feng X; Li C; Li Y; Ma J; Liu Y; Zhou A; Shou J
    Cancer Res Treat; 2021 Oct; 53(4):1156-1165. PubMed ID: 33592141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bladder sparing surgery in high-grade bladder cancer.
    Yakovlev PG; Klyushin DA; Vereshchako RI
    Exp Oncol; 2019 Jun; 41(2):160-165. PubMed ID: 31262149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bladder preservation multimodality therapy as an alternative to radical cystectomy for treatment of muscle invasive bladder cancer.
    Maarouf AM; Khalil S; Salem EA; ElAdl M; Nawar N; Zaiton F
    BJU Int; 2011 May; 107(10):1605-10. PubMed ID: 20825396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment strategies using transurethral surgery, chemotherapy, and radiation therapy with selection that safely allows bladder conservation for invasive bladder cancer.
    Kanady KE; Shipley WU; Zietman AL; Kaufman DS; Althausen AF; Heney NM
    Semin Surg Oncol; 1997; 13(5):359-64. PubMed ID: 9259092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of immediate radical cystectomy in the treatment of patients with residual T1 bladder cancer on restaging transurethral resection.
    Sternberg IA; Keren Paz GE; Chen LY; Herr HW; Dalbagni G
    BJU Int; 2013 Jul; 112(1):54-9. PubMed ID: 23146082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathologic response in patients receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer: Is therapeutic effect owing to chemotherapy or TURBT?
    Brant A; Kates M; Chappidi MR; Patel HD; Sopko NA; Netto GJ; Baras AS; Hahn NM; Pierorazio PM; Bivalacqua TJ
    Urol Oncol; 2017 Jan; 35(1):34.e17-34.e25. PubMed ID: 27639777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Commentary on "A novel treatment strategy for newly diagnosed high-grade T1 bladder cancer: Gemcitabine and cisplatin adjuvant chemotherapy-A single-institution experience.".
    Yang GL; Zhang LH; Liu Q; Wang ZL; Duan XH; Huang YR; Bo JJ
    Urol Oncol; 2018 Jul; 36(7):346-347. PubMed ID: 29859729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced Quality and Effectiveness of Transurethral Resection of Bladder Tumour in Non-muscle-invasive Bladder Cancer: A Multicentre Real-world Experience from Scotland's Quality Performance Indicators Programme.
    Mariappan P; Johnston A; Padovani L; Clark E; Trail M; Hamid S; Hollins G; Simpson H; Thomas BG; Hasan R; Bhatt J; Ahmad I; Nandwani GM; Mitchell IDC; Hendry D;
    Eur Urol; 2020 Oct; 78(4):520-530. PubMed ID: 32690321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel treatment strategy for newly diagnosed high-grade T1 bladder cancer: Gemcitabine and cisplatin adjuvant chemotherapy-A single-institution experience.
    Yang GL; Zhang LH; Liu Q; Wang ZL; Duan XH; Huang YR; Bo JJ
    Urol Oncol; 2017 Feb; 35(2):38.e9-38.e15. PubMed ID: 28040419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initial results of retrospective study: preoperative transurethral excision plus chemotherapy and radiation therapy and trial of bladder preservation.
    Gamal El-Deen HS
    J Egypt Natl Canc Inst; 2007 Jun; 19(2):133-46. PubMed ID: 19034344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.